Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb

Brussels, Belgium

Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb

Brussels, Belgium

Time filter

Source Type

Sculier J.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Meert A.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Berghmans T.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb
European Respiratory Review | Year: 2014

The objective of this review is to report the Clinical Year in Review proceedings in the field of thoracic oncology that were presented at the 2013 European Respiratory Society Annual Congress in Barcelona, Spain. Various topics were reviewed, including: epidemiology, screening, histology, and treatment of nonsmall cell lung cancer and small cell lung cancer. © ERS 2014.


Sculier J.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb
Revue des Maladies Respiratoires Actualites | Year: 2015

The TNM classification has changed in 2009 on the basis of a new methodological approach. The various modifications of the system and the associated works are reviewed. The potential improvements in prognostic and operational terms are discussed. © 2015 Elsevier Ltd.


Berghmans T.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb
Revue des Maladies Respiratoires Actualites | Year: 2014

Over 85 % of patients with non small cell lung carcinoma (NSCLC) have no EGFR activating mutation, their management in first line treatment is the daily life of doctors who have interest in lung cancer. Chemotherapy proved to be useful compared to supportive care from many years. The standard chemotherapy regimen should be a platinumbased combination, first with cisplatin if the patient's condition and comorbidities allow it. Combination therapy rather than monotherapy is beneficial, including elderly patients or those with a performance status 2. If cisplatin can't be used, a combination therapy with or without carboplatin can be chosen. The choice of the second agent. in combination with cisplatin should be guided by the potential side effects and the histology, strategies based on the presence of an overactivation of some proteins (for example ERCC1) have not yet proven their effectiveness. Except adding bevacizumab to combination therapy, there is no place for targeted therapies in first-line treatment of NSCLC. © 2014 Elsevier Masson SAS.


Sculier J.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Berghmans T.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Meert A.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb
European Respiratory Review | Year: 2015

Herein, we have reviewed and analysed recent literature, published in 2013 and early 2014, in the context of pre-existing data. Considered target therapies were tyrosine kinase inhibitors of active epidermal growth factor receptor mutations (e.g. erlotinib, gefinitib and afatinib), anaplastic lymphoma kinase rearrangements (e.g. crizotinib) or angiogenesis (drugs under development), or monoclonal antibodies against vascular endothelial growth factor (e.g. bevacizumab) or epidermal growth factor receptors (e.g. cetuximab). The therapeutic project has to consider tyrosine kinase inhibitors in the case of nonsmall cell lung cancer with active epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangement. However, these drugs should not be used in the absence of the targeted genetic abnormalities. ©ERS 2015.


Berghmans T.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Lafitte J.-J.,Lille University of Science and Technology | Scherpereel A.,Lille University of Science and Technology | Ameye L.,Institute Jules Bordet | And 7 more authors.
ERS Monograph | Year: 2015

Salvage chemotherapy (CT) for relapsing or refractory small cell lung cancer (SCLC) remains disappointing. In vitro experiments showed that valproic acid increases apoptosis of SCLC cell lines exposed to doxorubicin, vindesine and bis(2-chloroethyl)amine. The primary objective of this phase II study was to determine whether epigenetic modulation with valproic acid in addition to a doxorubicin, vindesine and cyclophosphamide (VAC) regimen improves 6-month progression-free survival (PFS). Patients with pathologically proven SCLC refractory to prior platinum derivatives and etoposide were eligible. After central registration, patients received VAC plus daily oral valproic acid. 64 patients were registered, of whom six were ineligible. Seven patients did not receive any CT, leaving 51 patients assessable for the primary end-point. The objective response rate was 19.6%. Median PFS was 2.8 months (95% CI 2.5-3.6 months) and 6-month PFS was 6%. Median survival time was 5.9 months (95% CI 4.7-7.5 months). Toxicity was mainly haematological, with 88% and 26% grade 3-4 neutropenia and thrombopenia, respectively. Despite an interesting response rate, the addition of valproic acid to VAC did not translate into adequate PFS in relapsing SCLC or SCLC refractory to platinum-etoposide. © ERS 2015.


Sculier J.P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Botta I.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Bucalau A.M.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Compagnie M.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | And 9 more authors.
Lung Cancer | Year: 2015

Comorbidities are frequent in patients with lung cancer, who are often treated with systemic anticancer therapy. The purpose of the present review is to report the adaptations recommended for the various drugs used in lung cancer treatment, in the context of a specific comorbidity. The literature was reviewed for neurologic, endocrine, hepatic, renal, digestive, cardiovascular, pulmonary, blood and systemic diseases. The comorbidities impact on the systemic anticancer treatment is poorly assessed. There are no good data with a high level of evidence and literature is often limited to experts' opinion and to case reports. We need to improve our knowledge about those patients by adequate multicentric and prospective studies and registries in order to offer them better care in term of evidence-based medicine. © 2015.


Meert A.P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Berghmans T.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Markiewicz E.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Hardy M.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | And 3 more authors.
Journal of B.U.ON. | Year: 2011

Purpose: Prior non invasive ventilation (NIV) is associated with an increased mortality in patients with haematological malignancies and acute respiratory failure treated by invasive mechanical ventilation (IMV). We have assessed whether NIV failure is an independent prognostic factor for hospital discharge in a general cancer population treated by IMV. Methods: 106 patients with solid tumors and 58 patients with haematological malignancies were eligible for this retrospective study; 41 were treated by NIV before IMV. Results: The main indications for mechanical ventilation were sepsis/shock (35%), acute respiratory failure (33%), cardiopulmonary resuscitation (16%) and neurologic disease (10%). Respectively, 35%, 28% and 24% of the patients were extubated, discharged from the intensive care unit (ICU) and from the hospital. For patients treated with NIV prior to IMV, the rates were 22%, 17% and 10%, respectively. In multivariate analysis, 3 variables were independently associated with a decreased probability of being discharged from the hospital: NIV use before IMV (odds ratio/OR=0.30, 95% confidence interval/CI: 0.09-0.95; p=0.04); leukopenia (OR=0.21,95% CI: 0.06-0.77; p=0.02) and serum bilirubin >1.1 mg/dl (OR=0.38,95% CI: 0.16-0.94; p=0.04). Conclusion: NIV failure before IMV is an independent poor prognostic factor in cancer patients treated by IMV. © 2011 Zerbinis Medical Publications.


Morelle I.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Berghmans T.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Cstoth I.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Sculier J.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Meert A.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb
Revue des Maladies Respiratoires | Year: 2014

In Belgium in 2008, the body responsible for compensating and indemnifyingvictims of occupational diseases recognized 62 cases of lung cancer, although 702 cases wereexpected. There is an 'underreporting' of occupational lung cancer. This study aimed to assessthe number of cases of occupational lung cancer in a Belgian hospital specialized in oncology.Patient and method. - From September 1st, 2009 to January 31st, 2011, each new patientwith lung cancer has been directed to a consultation identifying occupational exposure to lungcarcinogens.Results. - Among 81 occupational histories, 28 patients (35%) were found to have been defini-tely or probably exposed to one or more lung carcinogens (known or suspected). These patientswere all male, mostly blue collar workers. Thirteen compensation claims for occupationaldisease have been introduced: nine recognized, one rejected and three pending.Conclusion. - This study demonstrates the importance of a physician trained in occupationaldiseases within a thoracic oncology unit in reducing the 'underreporting' of occupational lungcancer and thus providing the victims with the compensation to which they are legitimatelydue.© 2013 SPLF. Published by Elsevier Masson SAS. All rights reserved.


PubMed | Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb
Type: Journal Article | Journal: European respiratory review : an official journal of the European Respiratory Society | Year: 2015

Herein, we have reviewed and analysed recent literature, published in 2013 and early 2014, in the context of pre-existing data. Considered target therapies were tyrosine kinase inhibitors of active epidermal growth factor receptor mutations (e.g. erlotinib, gefinitib and afatinib), anaplastic lymphoma kinase rearrangements (e.g. crizotinib) or angiogenesis (drugs under development), or monoclonal antibodies against vascular endothelial growth factor (e.g. bevacizumab) or epidermal growth factor receptors (e.g. cetuximab). The therapeutic project has to consider tyrosine kinase inhibitors in the case of nonsmall cell lung cancer with active epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangement. However, these drugs should not be used in the absence of the targeted genetic abnormalities.


PubMed | Grand Hopital de Charleroi, Lille University of Science and Technology, University of Liège, CH Mouscron and 2 more.
Type: Journal Article | Journal: ERJ open research | Year: 2016

Salvage chemotherapy (CT) for relapsing or refractory small cell lung cancer (SCLC) remains disappointing.

Loading Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb collaborators
Loading Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb collaborators